Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02184195 · ClinicalTrials.gov registry record · Phase 3
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 154
- Enrollment target
NCT02184195 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 154 participants.
The verdict
NCT02184195, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 154 participants
- Enrollment target
Study Summary
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Interventions
- DRUG Placebo
- DRUG Olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2014-12-16 |
| Est. Completion | 2023-01-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02184195
The ClinicalTrials.gov registry entry for NCT02184195 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02184195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02184195 about?
NCT02184195 is a clinical study titled "Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy". A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
What is the current status of trial NCT02184195?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 154 participants. The study started on 2014-12-16. Estimated completion is 2023-01-27.
What interventions are being tested in trial NCT02184195?
The interventions under investigation include: Placebo (DRUG), Olaparib (DRUG).
Who is sponsoring clinical trial NCT02184195?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.